GLP-1semaglutidetirzepatidepsoriasisixekizumab

Review finds GLP-1 agonists improve psoriasis severity alongside weight loss

The phase 3b TOGETHER trial showed greater skin clearance with ixekizumab plus tirzepatide than ixekizumab alone in patients with overweight or obesity.

By Maren Holt · Senior Reporter, GLP-1

Sep 30 20:00 ETSource: Clinics in dermatology

The wire

01A Clinics in Dermatology review of randomized and observational data on liraglutide, semaglutide, exenatide, dulaglutide and tirzepatide reports improvements in psoriasis severity, inflammatory biomarkers and quality of life.
02TOGETHER-PsA showed psoriatic arthritis improvement as early as week 4, before meaningful weight loss, supporting weight-independent anti-inflammatory effects relevant to dermatology prescribing.
03Most observational studies were small and uncontrolled; the authors call for trials in patients without obesity or diabetes to separate weight loss from direct anti-inflammatory effects.

From the source

GLP-1 receptor agonists in psoriasis management
Clinics in dermatology · 2026 Oct 1 · Cutrona M, Talia J, Cices A et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42822650/